Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Operating Income (2019 - 2026)

Enliven Therapeutics has reported Operating Income over the past 8 years, most recently at -$27.8 million for Q1 2026.

  • Quarterly results put Operating Income at -$27.8 million for Q1 2026, up 12.21% from a year ago — trailing twelve months through Mar 2026 was -$17.9 million (up 83.76% YoY), and the annual figure for FY2025 was -$21.8 million, up 79.17%.
  • Operating Income reached -$27.8 million in Q1 2026 per ELVN's latest filing, down from $63.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $63.6 million in Q4 2025 and bottomed at -$31.7 million in Q1 2025.
  • Median Operating Income over the past 5 years was -$24.2 million (2023), compared with a mean of -$16.3 million.
  • The largest annual shift saw Operating Income crashed 123.64% in 2023 before it skyrocketed 336.46% in 2025.
  • Over 5 years, Operating Income stood at -$10.2 million in 2022, then crashed by 123.64% to -$22.7 million in 2023, then dropped by 18.33% to -$26.9 million in 2024, then soared by 336.46% to $63.6 million in 2025, then crashed by 143.75% to -$27.8 million in 2026.
  • Business Quant data shows Operating Income for ELVN at -$27.8 million in Q1 2026, $63.6 million in Q4 2025, and -$25.1 million in Q3 2025.